Sandoz India Pvt Ltd company information, Employees & Contact Information

Corporate Governance Sandoz

Annual General Meeting Sandoz

Sandoz further asserts leadership in biosimilars, breaking GlobeNewswire

Product Safety Notices Sandoz

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed GlobeNewswire

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations Sandoz

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France Sandoz

Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar Sandoz

Watch Richard Saynor's BBC interview on the future of affordable medicines Sandoz

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications Sandoz

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars Sandoz

Business Sandoz

News Archive Sandoz

Sandoz joins Energize Program to support suppliers in decarbonization efforts Sandoz

Generics Sandoz

About Sandoz Sandoz

Sandoz Issues Recall of One Lot of Enoxaparin Sandoz

Sandoz signs Science Based Targets Initiative (SBTi) Commitment Letter Sandoz

Media Sandoz

Environment Sandoz

Driving impact and access Sandoz

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] Sandoz

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation Novartis

Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote Novartis

Sandoz appoints new Board representative to global AMR Industry Alliance Novartis

Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe Novartis

Novartis confirms Sandoz Spin-off for October 4, 2023 Novartis

Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements Novartis

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs Novartis

Novartis shareholders approve the proposed 100% Spin-off of Sandoz Novartis

Sandoz receives FDA approval for aflibercept-abzv for the treatment of nAMD Ophthalmology Times

Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio Yahoo Finance

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access Novartis

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) Novartis

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine Novartis

Sandoz: Provider of Customized Solutions in Biotech Manufacturing August 2014 BioProcess International

Stability and Degradation Pathways of N-Nitroso-Hydrochlorothiazide and the Corresponding Aryl Diazonium Ion ACS Publications

Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) Novartis

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines GlobeNewswire

Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine Novartis

Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Novartis

Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines PR Newswire

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder Novartis

Sandoz proposed biosimilar rituximab accepted for review by the FDA Novartis

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) Novartis

Orphenadrine Recalled Due to Possible Nitrosamine Impurity Medscape

High Temperature Exposure Prompts Recall of Anticoagulant Med Medical Professionals Reference

Top five generic drug makers European Pharmaceutical Review

Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab Novartis

Sandoz and Novartis recall prescription drug blister packages due to failure to meet child-resistant closure requirements The Columbus Dispatch

Sandoz enters new era as standalone global leader in generic and biosimilar medicines PR Newswire Canada

Sandoz recalls blood pressure medication because the bottles are not child resistant fox43.com

Sandoz Recalls Estarylla Birth Control Pills Medscape

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Macau Business

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Koreabizwire

Blood pressure, cholesterol medications recalled for child-resistant cap failure KUSA.com

Sandoz signs landmark supply and manufacturing agreement The Globe and Mail

Sandoz voluntarily recalls 10 lots of Introvale birth control pills CBS News

Sandoz Philippines names new Country Head Novartis

Sandoz Reports Q1 2025 Net Sales in Line with Company Expectations; Full-year Guidance Confirmed wahanariau.com

Co-amoxiclav powder for oral suspension alert Dispensing Doctors' Association